TGF-β transcriptional activity can also be inhibited by ER activation [13], thereby linking our research with pre-clinical and clinical studies showing that bisphosphonates only exert an anti-tumor effect under low estradiol concentrations [14, 15]. Here, TGFB1 is linked to neoplasm.